Company Overview
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.37.
Recent Developments
- Dec 2025 Revenue of $2.85M (+20.4% YoY); net profit $-143.44M.
- Trailing 12 Months Year-on-year growth — revenue +82.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.51% |
| 1 Year: | 82.70% |
Stock Price Performance
| 1 Year: | -38.02% |
| 6 Months: | -77.04% |
| 3 Months: | -29.69% |
| 1 Month: | +19.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 77.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UPB Upstream Bio, Inc. R2K | 7.27 | -2.51 | $395.63M | 0.00% | -47.12% | -41.83% | 9.51% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 621.00K | 640.00K | 510.00K | 607.00K | 566.00K | 937.00K | 683.00K | 1.03M |
| Operating Income | - | - | -9.39M | -15.01M | -17.54M | -18.89M | -32.01M | -44.35M | -37.83M | -43.62M |
| Net Income | -3.06M | -2.54M | -3.10M | -10.89M | -14.68M | -15.99M | -27.27M | -39.97M | -33.75M | -40.59M |
| Diluted EPS | - | - | -2.11 | -4.68 | -6.50 | -6.96 | -0.51 | -0.74 | -0.63 | -0.75 |
| R&D Expense | - | - | 7.79M | 11.69M | 14.07M | 15.43M | 25.80M | 37.87M | 32.98M | 36.56M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 2.38M | 2.37M | 2.85M |
| Operating Income | -40.11M | -77.76M | -160.36M |
| Net Income | -20.54M | -62.81M | -143.44M |
| Diluted EPS | -12.95 | -5.58 | -2.66 |
| R&D Expense | 31.80M | 62.97M | 136.81M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 117.20M | 481.72M | 353.77M |
| Total Equity | -106.16M | -123.13M | 469.85M | 339.77M |
| Cash & Equivalents | - | 25.83M | 325.89M | 101.58M |
| Total Liabilities | - | 9.39M | 11.87M | 14.00M |
| Current Liabilities | - | 6.51M | 10.74M | 13.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -37.93M | -59.17M | -133.28M |
| Investing Cash Flow | -82.84M | -59.48M | -93.48M |
| Financing Cash Flow | 129.55M | 418.91M | 2.44M |
| Capital Expenditure | -144.00K | -511.00K | -165.00K |
| Free Cash Flow | -38.07M | -59.68M | -133.44M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -1,685.5% | -3,281.2% | -5,618.8% |
| Net Margin % | -862.9% | -2,650.0% | -5,026.0% |
| ROE % | 16.7% | -13.4% | -42.2% |
| ROCE % | -36.2% | -16.5% | -47.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.89% | 8.10M | $58.49M |
| 2 | Orbimed Advisors LLC. | 10.46% | 5.69M | $41.11M |
| 3 | Blackrock Inc. | 6.19% | 3.37M | $24.34M |
| 4 | Decheng Capital LLC | 5.01% | 2.72M | $19.67M |
| 5 | Enavate Sciences Gp, LLC | 4.52% | 2.46M | $17.76M |
| 6 | Vanguard Capital Management LLC | 3.44% | 1.87M | $13.53M |
| 7 | Federated Hermes, Inc. | 1.80% | 979.76K | $7.07M |
| 8 | Geode Capital Management, LLC | 1.75% | 950.62K | $6.86M |
| 9 | Millennium Management Llc | 1.72% | 937.32K | $6.77M |
| 10 | Seb Asset Management Ab | 1.61% | 878.47K | $6.34M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UPB
Why Did UPB Stock Plunge 40% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSzA5R0d3U2QyOTh2ckpOUFRCUk9oWENLWDdvRDNMODZMYnpuQmlSbmNSQURRTTQtV2k2Y2xhcGlIMTV5V3ZEUUZEWkZ4VUd6cDV3MUI4Q2NrWjFIX1hZY1lHbWViS2g5UjdEUW4tZHdZaTJtUXY1MHhyRm9RUEdjR0pQTVh3WDRPMllNRm…
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPWTlUOFg1MFRIZ1BmWEVRTTNxbzVvTzhBem9pREIwS3M3WVRleVpBQWdwSlBaZFg0VTBMYV9nSTZNTTBDYWlwelpDVTV1d0NrZTktaTBoNjlodzhOY0Y2MmpsNG5IYmx1NlZrblU2QnF1QkxrU3I5SEl6VzVvc3h0TVVwdmlyS3plX3Ewel…
Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPTlNqQ2UySlVPcG40Z0hPSXM0cGtJb0k3M1Q3Q0hOdFJxQXQyNzNoRmpsTXRoNWxPbjhJQldyeWNzZW9VRm9GY1h4SlpXTGlPcXhoc2g3Y0ZHc0pPaGhMVGVZNXU3dDRKZVh6d0Exa0M2NFZBSUY3T3owSU1TMkphVkY0VUZQaGJqSkZHcl…
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPN0dxNnhiVkgwWHRxNnBwbDZ6RnFIM0xkUU5vVVIteWEzanJGRzBkMkVobEExLXJTY0hwSGFkRnJDcUpxU1NfVUJ0VnhkTmRreXFrVDU0UndxSG9WT3JXeUZQOXdUQTByYUcwdGFJbUdhazdyZGR1cmVtY2RkeXExNno5c0YzV0xVTFRDNl…
$UPB stock is up 7% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPTWVyTGJxM1Q2WmduTEhRRzBIbmQyUUlJU1FKOFp6TG1wSUFXa0hzeEIzTnI2bFJqN1c3cldRWk5wdVYwOG1GeEhuQk0zc2lKYzRwZUZBNnllckt4ZDB5bzVWdlhOUG1Ja0pESk5lLThJYmNrRWlxQmpFeDNjRERrc3l6R0NBS2dqZ0wxQT…
Price to book forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPNnNEMTFxSUU1cWozWXdTOHZpY1Z5dnQ3a2xlM3Bsb0pkR1c4N2pNdmdObWY5SVAxSEFBaUsxTUJURXFkTzA5THF4VXQzYjF4VWtzZm5tcWFJdE1CU2kwUG9ncktON1NaalpnYzVpSzZxSm5uVVNualJGbEZUWkRiVlZYak9LdlFVNkhJYn…
UPB — Frequently Asked Questions
What is the current share price of Upstream Bio, Inc. (UPB)?
As of 2026-07-15 16:51 PDT, Upstream Bio, Inc. (UPB) trades at $7.27 on NasdaqGS. Its 52-week range is $5.92 to $32.60.
What is the market capitalisation of UPB?
Upstream Bio, Inc. (UPB) has a market capitalisation of $395.63M on NasdaqGS.
What is the P/E ratio of UPB?
UPB trades at a trailing price-to-earnings (P/E) ratio of -2.51. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.29.
What is the return on equity (ROE) of UPB?
UPB has a return on equity (ROE) of -41.83%. Its return on capital employed (ROCE) is -47.12%.
Is UPB a good stock to buy?
This page provides a data-driven analysis of Upstream Bio, Inc. (UPB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.